Welcome to our dedicated page for NovaBridge Biosciences SEC filings (Ticker: NBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NovaBridge Biosciences (NBP) SEC filings page on Stock Titan provides access to the company’s official disclosures as a foreign private issuer listed on Nasdaq. NovaBridge, formerly known as I-Mab, files reports such as Form 20-F and Form 6-K that describe its financial condition, risk factors, and operational progress as a global biotechnology platform company.
In these filings, NovaBridge outlines its business model, which combines business development and translational clinical development to advance a pipeline led by givastomig, ragistomig, uliledlimab, and VIS-101. Management’s discussion and analysis sections describe how the company allocates resources to oncology and ophthalmology programs, summarizes its collaborations with partners such as ABL Bio, and explains the structure of subsidiaries like Visara within its hub-and-spoke framework.
Investors reviewing NovaBridge’s SEC reports can examine clinical development disclosures for givastomig, including its positioning as a Claudin 18.2 x 4-1BB bispecific antibody in gastric and other gastrointestinal cancers, and for ragistomig as a PD-L1 x 4-1BB bispecific in solid tumors. Filings also discuss rights to uliledlimab outside Greater China and the VIS-101 license and assignment arrangements involving Visara and Everest Medicines.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as segment descriptions, collaboration agreements, share incentive plans, and subsequent events. Users can follow new 6-K submissions for interim updates, and consult annual filings for a more comprehensive view of NovaBridge’s strategy, risk profile, and pipeline.
By using this page, investors and researchers can monitor NovaBridge’s official SEC communications in real time, while AI-generated insights help interpret complex biotech and capital markets information contained in the original documents.
NovaBridge Biosciences reports results for the nine months ended September 30, 2025, highlighting a much smaller loss and a stronger cash position as it refocuses on a global biotech platform model. The net loss from continuing operations narrowed to $15.5 million from $38.9 million a year earlier, as research and development spending fell to $7.2 million and administrative expenses declined to $14.1 million after the divestiture of Greater China operations and internal restructuring.
The company ended the period with $228.1 million in cash and cash equivalents and $0.2 million in short-term investments, helped by a July underwritten offering that raised approximately $61.2 million in net proceeds. NovaBridge is pursuing a dual primary listing and IPO in Hong Kong, has adopted a platform structure using asset-focused subsidiaries, and expanded beyond oncology through Visara and the in-licensed ophthalmology asset VIS-101, while also acquiring Bridge Health to deepen its CLDN18.2 bispecific pipeline centered on lead asset givastomig.